W
ithin the pages of this issue of the Proceedings are featured five review articles, seven original research papers, a "Clinical Pearls and Pitfalls" paper and a "Patient-Oriented Problem Solving (POPS)" case report, all focusing on various aspects of allergy and respiratory disease. The lead review articles represent the proceedings of a chronic urticaria symposium presented at the Eastern Allergy Conference in June, 2013. In a complimentary pair of papers Weldon 1 and Lang 2 provide an update on chronic urticaria, its impact on patient quality of life (QOL), and evidence based diagnostic evaluation and treatment. Weldon 1 reviews the utility of QOL questionnaires which serve to document the benefit attributed to therapies. This is followed by Lang's 2 review, which suggests that extensive routine testing is not favorable from a cost-benefit standpoint, and does not lead to improved patient care outcomes. His review focuses on the attainment of improved outcomes for patients with chronic urticaria/angioedema based on evidence-directed recommendations. It not only provides the clinician with useful insights regarding the accurate diagnosis and management of patients with chronic urticaria, but also addresses the implications of recently published clinical trials demonstrating efficacy of omalizumab in this condition. Because of the significant potential patient benefit which may result from omalizumab, Lang's article is featured in this issue's "For the Patient" section. This newly introduced segment, found in the back of this issue and also available online, consists of a one page synopsis of a selected article, that is written in a readily comprehensible fashion to help patients better understand the content of the full article and its diagnostic and therapeutic implications. It is printed in a format to allow reproduction on the practitioner's letterhead for distribution to patients.
This issue continues with three review articles with topics ranging from idiopathic anaphylaxis to allergic rhinitis and finally sublingual immunotherapy. Lieberman 3 reviews the medical literature on idiopathic anaphylaxis with the goal of presenting a strategy for diagnosis, prevention, and treatment of episodes. He overviews recent advances which may help practitioners to diagnose anaphylaxis episodes due to mast cell activating syndromes, systemic mastocytosis, and IgE to galactose-alpha-1,3-galactose. Consolidating a theme from the last issue of the Proceedings 4-7 Sher and Ross 8 review the role of patient preference and satisfaction with intranasal corticosteroids and how these factors may affect patient adherence to therapy and patient outcomes. Cox 9 reviews the status of sublingual immunotherapy (SLIT) for aeroallergens in the United States, formulations of which have recently been favorably reviewed by the Federal Drug Administration, and discusses unresolved issues including unknown effective dose for many allergen extracts, optimal dosing schedule and timing of treatment initiation (perennial vs. pre-coseasonal, eight or more weeks before or just at the start of season), and whether epinephrine autoinjectors should be routinely prescribed for SLIT patients.
Continuing with the SLIT theme, Canonica et al 10 report on a survey of Italian allergy specialists to determine their rank order perception of importance of SLIT allergen extract characteristics. Their survey results show that Italian allergists rank the quality-related characteristics of allergen extracts as highly important when choosing products for allergy immunotherapy.
Information regarding the burden of illness due to hereditary angioedema (HAE) is limited. 11 In this issue, Caballero et al 12 comprehensively characterize the burden of illness and impact of HAE from the European patient perspective. They report that despite the availability of an improved standard of care, HAE patients still represent an unmet need, experiencing frequent and painful attacks, resulting in substantial impairment both physically and emotionally.
Combination therapy for asthma has been extensively studied, but not in patients with a recent asthma exacerbation. Hagiwara et al 13 retrospectively analyze a large health insurance dataset to determine the outcome of adding a long-acting beta agonist to inhaled corticosteroid (ICS) mono-therapy in a novel cohort of patients characterized by either a recent asthma exacerbation or frequent rescue medication utilization who received fluticasone propionate (FP) alone compared to fixed-dose FP/salmeterol combination (FSC). They report that in this subset of patients, receipt of FSC reduced asthma-related exacerbation risks and rescue medication utilization as compared to receipt of FP.
Continuing with the combination therapy for asthma theme, in an exclusive online publication also represented by an abstract printed in this issue, prescribing patterns for LABA-ICS combination therapy in Singapore are examined by Soh et al 14 as part of an assessment of asthma treatment practices and compliance with established international practice guidelines. They report that over a ten-year period, LABA-ICS patient prescriptions decreased significantly, especially in pre-schoolers (1-5 yrs) and that there was a corresponding rise in montelukast prescriptions. This move away from LABA-ICS combination especially in younger children, and a tendency towards more montelukast usage, is interpreted to be a reflection of practice preferences in accordance with current international guidelines in young children.
Transitioning topics to allergy skin testing, Nelson et al 15 examine the performance of a new single-site skin test device, UniTest PC (UT), that incorporates initial pressure to reduce the sensation of pain. Using two conventional prick skin testing devices as comparators, they report that all 3 devices were well tolerated, without a significant difference in perception of discomfort. Testing with histamine revealed differences in wheal size and reproducibility among the 3 devices and testing with saline revealed differing likelihood of inducing a significantly sized wheal.
The effect of breastfeeding on the risk of developing atopic disease remains controversial. Hong et al 16 report their investigation of the effect of breastfeeding on current atopic dermatitis (AD) among a large population of Korean children, ages 0 -13. They found that age and duration of maternal education were inversely associated with the prevalence of AD and that prolonged breastfeeding for longer than 12 months increased the risk of AD in the age group of children under the age of 5 years, regardless of parental history of atopic diseases.
Transitioning to the topic of food allergy, Vezir et al 17 present six patients who experienced systemic allergic reactions following ingestion of honey, three of the six patients manifesting true anaphylaxis. The authors characterize the six honey allergic patients in terms of honey specific serum IgE measurements, skin prick tests for honey, serum specific IgE for honey bee venom and skin prick tests to pollens. This issue also features a "Clinical Pearls and Pitfalls" section paper in which Badawi et al 18 presents a 48-year-old male with typical features of Schnitzler Syndrome, followed by a discussion of the pathogenesis and clinical aspects of this rare disease. Because this syndrome is associated with high morbidity and increased risk of lymphoproliferative neoplasms, it is hoped that this work will aid clinicians in its recognition and treatment.
Rounding out the issue is the most recent installment of the "POPS" series, which as per tradition, is written by an allergy-immunology fellow-in-training from one of the 73 US allergy-immunology training programs.
The purpose of the POPS series is to provide an innovative and practical learning experience for the allergist-immunologist using a format of clinical presentation, physical findings, appropriate laboratory studies, and differential diagnosis. Bajaj et al, 19 lead the reader through this process, describing the evaluation of a 52-year-old male with history of common variable immunodeficiency (CVID), who presented with three weeks of persistent high grade fevers of unknown origin, severe pancytopenia with shock and multi-organ failure. The reader is made aware of a rare but potentially fatal disease that can present in CVID patients.
In summary, the constellation of manuscripts found within the pages of this issue provides new insights regarding several important allergic and respiratory disorders afflicting patients who present to the allergist immunologist. In keeping with the overall mission of the Proceedings which is to distribute timely information regarding advancements in the knowledge and practice of allergy, asthma, and immunology to clinicians entrusted with the care of patients, it is our hope that the articles found within this issue achieve this goal and will help foster improved patient management through efficient workup and optimal therapy for a wide array of clinical problems seen in patients whom we serve. This collection of articles also illustrates the gravity of allergic and respiratory disorders seen in various patient populations, ranging across the full age spectrum from infancy to the elderly and from various regions around the world. The pathophysiologic mechanisms of allergic and respiratory disease are elegantly explored, illustrating critical insight into the etiology of these diseases and with the potential for future therapeutic innovations. On behalf of the editorial board, we hope you will enjoy the diversity of literature offered in this issue of the Proceedings. 
